OTTAVA

Ottava is a biotechnology company developing a platform for programmable, modular protein-based therapies. Founded by pioneers in genome editing and protein engineering, including David Liu and J. Keith Joung, the company aims to create smart medicines that can sense specific disease markers and execute therapeutic functions only when and where needed. This approach is designed to increase precision and reduce off-target effects in areas like oncology and immunology. By utilizing logic-gated protein circuits, Ottava seeks to overcome the limitations of traditional biologics and cell therapies, potentially enabling the treatment of diseases that were previously considered undruggable due to toxicity concerns.